16 Nov 2025
From pivotal trial to real-world impact: shaping TR treatment today with the EVOQUE system
Supported by Edwards Lifesciences
Summary
Rebecca Hahn, Varius Dannenberg and Matti Adam discuss the updated ESC/EACTS guidelines for tricuspid regurgitation, which upgrade transcatheter tricuspid interventions to a IIa recommendation. Evidence from the TRILUMINATE and TRISCEND II trials shows improved quality of life and reduced heart failure hospitalisations, especially in patients with massive TR or early-stage disease. Real-world registry data confirm the safety and consistent efficacy of #TTVR devices, highlighting their advantage over TEER in complex anatomies.
This interview was filmed at PCR London Valves 2025: see more videos here.